Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene launches HBV (hepatitis B virus) test for research use:

This article was originally published in Clinica

Executive Summary

Digene has launched a DNA test for hepatitis B based on its Hybrid Capture technology for use in measuring the effects of antiviral therapies in US patients. HBV is the second most common chronic infectious disease in the world, affecting 350 million people and killing one million every year. The test, which is already used outside the US, detects the virus and measures viral load in response to therapy. Use in the US will be limited to drug research until the FDA has cleared it for clinical use.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel